Log in to search using one of your social media accounts:

 

Amgen launches Enbrel Mini single-dose cartridges with reusable auto-injector
Amgen (NSDQ:AMGN) announced today the U.S. launch of its Enbrel Mini single-dose prefilled cartridges delivered using its reusable AutoTouch auto-injector. The drug-device combination was designed with a needle that stays hidden during injection and a sensor to detect placement on the skin. Get the full story at our sister site, Drug Delivery Business News. The post Amgen launches Enbrel Mini single-dose cartridges with reusable auto-injector appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 17, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Orthopedics Pharmaceuticals Wall Street Beat Amgen Source Type: news

Amgen Launches The ENBREL Mini(TM) Single-Dose Prefilled Cartridge With AutoTouch(TM) Reusable Autoinjector That Is Ergonomically Designed For Patients
Innovative Reusable Autoinjector Provides Additional Administration Option for Enbrel® (Etanercept) Users Awarded Arthritis Foundation Ease of Use (SM) Commendation THOUSAND OAKS, Calif., Nov. 17, 2017 -- (Healthcare Sales & Marketing Network) -... Biopharmaceuticals, Devices, Drug Delivery, Product Launch Amgen, ENBREL Mini, Enbrel, Etanercept, autoinjector (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 17, 2017 Category: Pharmaceuticals Source Type: news

Amgen Launches The ENBREL Mini ™ Single-Dose Prefilled Cartridge With AutoTouch™ Reusable Autoinjector That Is Ergonomically Designed For Patients
Innovative Reusable Autoinjector Provides Additional Administration Option for Enbrel® (Etanercept) Users Awarded Arthritis Foundation Ease of Use (SM) Commendation THOUSAND OAKS, Calif., Nov. 17, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that the ENBREL Mini™ with AutoTouch™ is now available in the United States (U.S.). Awarded the Arthritis Foundation Ease of UseSM Commendation, this new and innovative delivery system provides an additional administration option for appropriate ENBREL patients. The AutoTouch™ reusable autoinjector has an ergonomic design that includes feature...
Source: Amgen News Release - November 17, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Patients' drugs fail to arrive  at their homes
The 42-year-old teacher has ankylosing spondylitis — a type of inflammatory arthritis which mainly affects the spine — and has been treating it with injections of etanercept since 2009. (Source: the Mail online | Health)
Source: the Mail online | Health - November 14, 2017 Category: Consumer Health News Source Type: news

The patients left in despair as drugs fail to arrive  
The 42-year-old teacher has ankylosing spondylitis — a type of inflammatory arthritis which mainly affects the spine — and has been treating it with injections of etanercept since 2009. (Source: the Mail online | Health)
Source: the Mail online | Health - November 14, 2017 Category: Consumer Health News Source Type: news

Godly gift for arthritis pain
Big Pharma is at it again… Creating and selling a drug that causes thousands of heart attacks and strokes each year. In 2015, the FDA asked drug makers to strengthen their warning labels. Since then, most have listed their dangerous side effects on the bottle. But one manufacturer thought they didn’t have to warn people about their dangerous drug. They marketed their product as a “unique” breakthrough. They even published studies promising it was “safe for long-term use.” 1 The drug is a 7-year-old arthritis drug called Actemra. It’s made by the Swiss pharmaceutical company Roche....
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

MRI Shows Bone Repair in Treated Spine Disease (CME/CE)
(MedPage Today) -- Structural lesions improved with etanercept in nonradiographic axial spondyloarthritis (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - October 2, 2017 Category: Primary Care Source Type: news

Sandoz ’s Erelzi available for multiple inflammatory disease treatment in Canada
Novartis division Sandoz has made its Erelzi (etanercept) therapy available for the treatment of multiple inflammatory diseases for patients in Canada. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 21, 2017 Category: Pharmaceuticals Source Type: news

Pfizer revenue misses on lower Prevnar, Enbrel sales
(Reuters) - Pfizer Inc reported quarterly revenue on Tuesday that missed Wall Street estimates, driven by lower demand for its rheumatoid arthritis treatment Enbrel and pneumonia vaccine Prevnar. (Source: Reuters: Health)
Source: Reuters: Health - August 1, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Pfizer quarterly revenue slips 2 percent
(Reuters) - Pfizer Inc reported a nearly 2 percent drop in quarterly revenue on Tuesday, driven by lower demand for its rheumatoid arthritis treatment Enbrel and pneumonia vaccine Prevnar. (Source: Reuters: Health)
Source: Reuters: Health - August 1, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Saving Vanessa, part 1: A mystery rash, a stroke and an epic rescue
Vanessa’s rash first appeared on her arms and legs when she 3 or 4 months old. It was red and bumpy and went away when she was sick with a virus, which happened often. Then it would come back. The dermatology team she saw at Boston Children’s Hospital was puzzled. “I was expecting they were going to think it was nothing, but they took it very seriously,” says Katherine Bell, one of Vanessa’s mothers. “They took a biopsy and very quickly realized they had no idea what it was.” Vanessa’s case was even featured at a regional dermatology conference where doctors take up mystery p...
Source: Thrive, Children's Hospital Boston - July 25, 2017 Category: Pediatrics Authors: Nancy Fliesler Tags: Diseases & Conditions Our Patients’ Stories Dr. Carolyn Rogers Dr. Pui Lee Dr. Robert Sundel Dr. Scellig Stone Dr. Todd Lyons stroke Source Type: news

Novartis unit Alcon posts modest Q2 gain
(Reuters) — Long-suffering Novartis (NYSE:NVS) unit Alcon‘s sales growth accelerated in the second quarter, boosting options for the business including a possible disposal, CEO Joe Jimenez said today. The eye care subsidiary’s sales rose 1% to $1.5 billion, including intraocular lens revenues, which grew for the first time in the second quarter since 2014. Spending continued to promote products with eye surgeons, resulting in a $19 million operating loss. Novartis has been reviewing Alcon for a possible disposal, with an update slated for this year. All options are under consideration, Jimenez reiter...
Source: Mass Device - July 18, 2017 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Mergers & Acquisitions Optical/Ophthalmic Wall Street Beat Alcon Novartis Source Type: news

Novartis gets European OK for biosimilar of Amgen's Enbrel
ZURICH (Reuters) - Novartis's generics unit Sandoz said the European Commission approved Erelzi, its biosimilar to Amgen's Enbrel, to treat inflammatory diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis. (Source: Reuters: Health)
Source: Reuters: Health - June 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

In Rheumatoid Arthritis, Adding a Biologic Agent Before Trying Triple Therapy Likely Not Cost-Effective (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH For patients with active rheumatoid arthritis despite methotrexate therapy, adding a biologic agent (e.g., etanercept) before trying triple therapy would lead to substantial cost increases without much … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 30, 2017 Category: Primary Care Source Type: news

Cost controls help offset lower Amgen first-quarter drug sales
(Reuters) - Amgen Inc on Wednesday reported higher-than-expected first-quarter profit as cost controls helped offset a sharp drop in sales of Enbrel, its blockbuster rheumatoid arthritis and psoriasis drug. (Source: Reuters: Health)
Source: Reuters: Health - April 26, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Your NEJM Group Today: Histology Rings True / Probiotics for C. diff / Illinois IM Opportunity (FREE)
By the Editors Here's today's offering from NEJM Group:NEJM Clinical Practice Center: Clinical Problem-Solving: A 58-year-old man with nonerosive rheumatoid arthritis who was being treated with etanercept … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 6, 2017 Category: Primary Care Source Type: news

Amgen Reports Fourth Quarter And Full Year 2016 Financial Results
THOUSAND OAKS, Calif., Feb. 2, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2016. Key results include: For the fourth quarter, total revenues increased 8 percent versus the fourth quarter of 2015 to $6.0 billion. Product sales grew 6 percent driven by Enbrel® (etanercept), Prolia® (denosumab), Repatha® (evolocumab) and KYPROLIS® (carfilzomib). For the full year, total revenues increased 6 percent to $23.0 billion, with 5 percent product sales growth. GAAP earnings per share (EPS) increased 9 percent in the fourth ...
Source: Amgen News Release - February 2, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Novartis says court battle will delay its Enbrel copy until 2018 at least
ZURICH (Reuters) - The Novartis copy of Amgen's blockbuster psoriasis drug Enbrel will not go on sale before 2018 at the earliest because of the U.S. company's patent protection challenge, the Swiss drugmaker's head of generics told Reuters. (Source: Reuters: Health)
Source: Reuters: Health - January 25, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Slight, Nonsignificant CV Risk with Actemra vs Enbrel
(MedPage Today) -- Few events seen with either agent (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - November 29, 2016 Category: Journals (General) Source Type: news

Enbrel (Etanercept) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 18, 2016 Category: Drugs & Pharmacology Source Type: news

Actemra Carries Slight Increase in Heart Risk vs. Enbrel
(MedPage Today) -- But efficacy, too, must be weighed in treatment decisions (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 17, 2016 Category: Cardiology Source Type: news

FDA OKs Etanercept (Enbrel) for Kids With Plaque Psoriasis FDA OKs Etanercept (Enbrel) for Kids With Plaque Psoriasis
Etanercept becomes the first biologic approved for children aged 4 years and older with moderate-to-severe plaque psoriasis.FDA Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - November 8, 2016 Category: Dermatology Tags: Dermatology News Alert Source Type: news

Data To Be Presented At ACR/ARHP 2016 Annual Meeting Show Amgen's Ongoing Commitment To Therapies For Patients With Serious Inflammatory And Bone Diseases
21 Abstracts to be Featured Provide Real-World and Disease State Insights, Highlight Clinical and Health Economic Impact of Rheumatologic Diseases and Osteoporosis THOUSAND OAKS, Calif., Nov. 7, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from multiple studies related to Enbrel® (etanercept), Prolia® (denosumab) and AMJEVITA™ (adalimumab-atto), as well as investigational candidates, including ABP 710 (infliximab biosimilar candidate) and romosozumab, at the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual...
Source: Amgen News Release - November 7, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves Expanded Use Of ENBREL ® (etanercept) To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasis
First and Only Systemic Drug Approved in the U.S. to Treat Children Affected by This Serious Inflammatory Disease THOUSAND OAKS, Calif., Nov. 4, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of ENBREL® (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis. "As many parents of children with moderate-to-severe plaque psoriasis can tell you, there is a n...
Source: Amgen News Release - November 4, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves Expanded Use of Enbrel (etanercept) to Treat Children with Chronic Moderate-To-Severe Plaque Psoriasis
THOUSAND OAKS, Calif., Nov. 4, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of Enbrel (etanercept),... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 4, 2016 Category: Drugs & Pharmacology Source Type: news

Erelzi (etanercept-szzs) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 12, 2016 Category: Drugs & Pharmacology Source Type: news

A Push to Lower Drug Prices That Hit Insurers and Employers the Hardest
Seeking to force drug price competition in an expensive category, the company wants insurers to cover fewer anti-inflammatory drugs, at least as a first-line treatment. (Source: NYT Health)
Source: NYT Health - September 8, 2016 Category: Consumer Health News Authors: KATIE THOMAS Tags: Express Scripts Inc Drugs (Pharmaceuticals) Health Insurance and Managed Care Prices (Fares, Fees and Rates) Enbrel (Drug) Humira Source Type: news

New Version of RA Drug Enbrel: FAQ
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - September 2, 2016 Category: Journals (General) Source Type: news

New Version of RA Drug Enbrel: FAQ
Title: New Version of RA Drug Enbrel: FAQCategory: Health NewsCreated: 9/2/2016 12:00:00 AMLast Editorial Review: 9/2/2016 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - September 2, 2016 Category: Rheumatology Source Type: news

New Version of RA Drug Enbrel: FAQ
The FDA cleared the way for what is hoped may be a more affordable version of the popular arthritis drug Enbrel. Tuesday the agency approved Erelzi (etanercept-szzs), a "biosimilar" to Enbrel. (Source: WebMD Health)
Source: WebMD Health - September 1, 2016 Category: Consumer Health News Source Type: news

Monthly News Roundup - August 2016
FDA Approves Erelzi: Sandoz ’s Biosimilar For Enbrel A third U.S. biosimilar has been FDA-approved; this time it’s Erelzi (etanercept-szzs), a biosimilar to Amgen’s tumor necrosis factor (TNF) blocker Enbrel. Sandoz’s Erelzi is the first... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 31, 2016 Category: Pharmaceuticals Source Type: news

FDA Approves New Biological Drug for RA
Erelzi is a biosimilar for Enbrel (Source: WebMD Health)
Source: WebMD Health - August 31, 2016 Category: Consumer Health News Source Type: news

FDA Approves New Biological Drug for Rheumatoid Arthritis
WEDNESDAY, Aug. 31, 2016 -- A new biological drug to treat rheumatoid arthritis and other inflammatory diseases has been approved by the U.S. Food and Drug Administration. The drug Erelzi (etanercept-szzs) is a " biosimilar " to Enbrel (etanercept),... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 31, 2016 Category: Journals (General) Source Type: news

FDA Approves Erelzi Biosimilar for Enbrel
WEDNESDAY, Aug. 31, 2016 -- A new biological drug to treat rheumatoid arthritis and other inflammatory diseases has been approved by the U.S. Food and Drug Administration. The drug Erelzi (etanercept-szzs) is a " biosimilar " to Enbrel (etanercept),... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 31, 2016 Category: Journals (General) Source Type: news

Novartis bid to sell new biosimilar crimped by U.S. court battles
ZURICH (Reuters) - Novartis has won U.S. approval for a copy of Amgen's blockbuster arthritis drug Enbrel, but the Swiss drugmaker's bid to muscle in on the medicine's $4.7 billion in annual U.S. revenue remains blocked by court battles. (Source: Reuters: Health)
Source: Reuters: Health - August 31, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Etanercept Biosimilar
(MedPage Today) -- Erelzi will be licensed for all Enbrel's indications (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - August 31, 2016 Category: Dermatology Source Type: news

FDA Approves Erelzi (etanercept-szzs), a Biosimilar to Enbrel
August 30, 2016 -- The U.S. Food and Drug Administration today approved Erelzi, (etanercept-szzs) for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel (etanercept), which was originally licensed in 1998. Erelzi is administered by... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 31, 2016 Category: Drugs & Pharmacology Source Type: news

FDA OK's Novartis Biosimilar to Amgen Arthritis Drug, Enbrel
Sandoz, a division of Novartis, announces FDA approves Erelzi to treat multiple inflammatory diseases (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 30, 2016 Category: Pharmaceuticals Source Type: news

FDA OKs Biosimilar to Etanercept for Inflammatory Diseases FDA OKs Biosimilar to Etanercept for Inflammatory Diseases
Erelzi, a biosimilar to Enbrel, treats rheumatoid arthritis, among other disorders. It comes with a boxed warning about the risk for serious infections such as tuberculosis.FDA Approvals (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - August 30, 2016 Category: Pediatrics Tags: Rheumatology News Alert Source Type: news

FDA approves Novartis biosimilar to Amgen's Enbrel
WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Novartis AG's biosimilar version of Amgen Inc's arthritis drug Enbrel. (Source: Reuters: Health)
Source: Reuters: Health - August 30, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Biosimilar version of etanercept gains FDA approval
A biosimilar of etanercept received clearance for marketing from the Food and Drug Administration on Aug. 30 for all of the inflammatory disease indications held by the reference originator etanercept product, Enbrel, according to an announcement from the agency. Approval for all of Enbrel’s... (Source: Skin and Allergy News)
Source: Skin and Allergy News - August 30, 2016 Category: Dermatology Source Type: news

FDA approves Erelzi, a biosimilar to Enbrel
The U.S. Food and Drug Administration today approved Erelzi, (etanercept-szzs) for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel (etanercept), which was originally licensed in 1998. (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 30, 2016 Category: American Health Source Type: news

RheumNow: Could Etanercept Lower Alzheimer's Risk?
(MedPage Today) -- Epidemiological data warrant further study of TNF inhibitors (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - August 12, 2016 Category: Psychiatry Source Type: news

Amgen Profit Rises 13%, 2016 Outlook Raised
Amgen Inc. said its second-quarter earnings rose 13% on better-than-expected revenue growth, which was again driven by sales of key drugs such as Enbrel. (Source: WSJ.com: Health)
Source: WSJ.com: Health - July 27, 2016 Category: Pharmaceuticals Tags: PAID Source Type: news

Amgen 2nd-quarter profit tops Street view, raises 2016 forecast
(Reuters) – Amgen (NSDQ:AMGN) on Wednesday reported higher-than-expected 2nd-quarter profit on increased sales of its blockbuster rheumatoid arthritis drug Enbrel and newer medicines, and the company again raised its full-year forecast. The forecast appeared to signal management’s confidence in the 2nd half of the year. The company is on track to meet or exceed its long-term objectives,” Chief Executive Robert Bradaway said in a statement. Amgen said it now expects 2016 adjusted earnings per share of $11.10 to $11.40, up from its prior view of $10.85 to $11.20. Its midpoint is above of Wall...
Source: Mass Device - July 27, 2016 Category: Medical Equipment Authors: MassDevice Tags: Business/Financial News Drug-Device Combinations Amgen Source Type: news

Amgen Reports Second Quarter 2016 Financial Results
THOUSAND OAKS, Calif., July 27, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2016. Key results include: Revenues increased 6 percent versus the second quarter of 2015 to $5.7 billion. Product sales grew 5 percent driven by Enbrel® (etanercept), Prolia® (denosumab), KYPROLIS® (carfilzomib) and XGEVA® (denosumab). GAAP earnings per share (EPS) increased 15 percent to $2.47 driven by higher revenues and higher operating margins. GAAP operating income increased 15 percent to $2,380 million and GAAP operating margin improved by 3.8...
Source: Amgen News Release - July 27, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Makers of Humira and Enbrel Using New Drug Patents to Delay Generic Versions
Six years after the Affordable Care Act cleared the way for biosimilars, as the generic versions of biotechnology drugs are called, progress has been slow. (Source: NYT Health)
Source: NYT Health - July 16, 2016 Category: Consumer Health News Authors: ANDREW POLLACK Tags: Drugs (Pharmaceuticals) Biotechnology and Bioengineering Generic Brands and Products Prices (Fares, Fees and Rates) Amgen Inc AbbVie Inc Source Type: news

Biosimilar to Enbrel Unanimously Recommended by FDA PanelBiosimilar to Enbrel Unanimously Recommended by FDA Panel
The US Food and Drug Administration's Arthritis Advisory Committee unanimously recommended approval of GP2015 as a biosimilar to Enbrel (etanercept). Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 14, 2016 Category: Consumer Health News Tags: Dermatology News Source Type: news

Biosimilar to Enbrel Unanimously Recommended by FDA Panel Biosimilar to Enbrel Unanimously Recommended by FDA Panel
The US Food and Drug Administration's Arthritis Advisory Committee unanimously recommended approval of GP2015 as a biosimilar to Enbrel (etanercept). Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - July 14, 2016 Category: Dermatology Tags: Dermatology News Source Type: news

FDA advisory panel unanimously backs biosimilars for Humira, Enbrel
The Food and Drug Administration’s Arthritis Advisory Committee, together with an added complement of dermatologists and gastroenterologists, unanimously recommended during meetings on July 12 and 13 that the agency license a biosimilar Humira (adalimumab) that is made by Amgen and a biosimilar... (Source: Skin and Allergy News)
Source: Skin and Allergy News - July 13, 2016 Category: Dermatology Source Type: news